托珠单抗注射液致过敏性休克1例分析

doi:10.19803/j.1672-8629.20230594

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (3): 349-351.
DOI: 10.19803/j.1672-8629.20230594

托珠单抗注射液致过敏性休克1例分析

陈杰, 张斌, 赵俊, 张传洲^*

青岛大学附属医院药学部,山东青岛 266555

收稿日期:2023-09-21 出版日期:2024-03-15 发布日期:2024-03-18
通讯作者: ^*张传洲,男,硕士,副主任药师,临床药学。E-mail：mikechuanzhou@126.com
作者简介:陈杰,女,本科,副主任药师,医院药学。

One case of allergic shock caused by tocilizumab injection

CHEN Jie, ZHANG Bin, ZHAO Jun, ZHANG Chuanzhou^*

Department of Pharmacy, the Affiliated Hospital of Qingdao University, Qingdao Shandong 266555, China

Received:2023-09-21 Online:2024-03-15 Published:2024-03-18

摘要/Abstract

摘要： 目的分析托珠单抗注射液致过敏性休克的特点,为临床合理用药提供参考。方法报道1例儿童使用托珠单抗导致过敏性休克的案例,通过文献回顾托珠单抗导致过敏性休克的情况,并分析原因及防治措施。结果根据患者的临床表现及药物与用药时间的关联性,考虑托珠单抗导致过敏性休克,患者经有效抗过敏治疗后,过敏性休克症状得到缓解。结论临床应用托珠单抗应警惕过敏性休克等过敏情况,对严重过敏患者应禁止使用。

关键词: 托珠单抗, 注射液, 过敏性休克, 药品不良反应, 儿童

Abstract: Objective To analyze the characteristics of anaphylactic shock induced by tocilizumab injection in order to provide reference for clinical safe and rational drug use. Methods One case of anaphylactic shock caused by tocilizumab was analyzed. The related literature was reviewed while the causes, prevention and treatment of such adverse drug reactions were analyzed. Results According to the clinical manifestations of the patient and the correlation between the drug and the time of administration, this case of anaphylactic shock was considered to have been caused by tocilizumab. The symptoms of anaphylactic shock were relieved after effective anti-allergic treatment. Conclusion Clinicians should be wary of anaphylactic shock and other allergic conditions related to the use of tocilizumab, which should not be used in allergic patients.

Key words: tocilizumab, injection, allergic shock, adverse drug reaction, children

中图分类号:

陈杰, 张斌, 赵俊, 张传洲. 托珠单抗注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(3): 349-351.

CHEN Jie, ZHANG Bin, ZHAO Jun, ZHANG Chuanzhou. One case of allergic shock caused by tocilizumab injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 349-351.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230594

https://www.zgywjj.com/CN/Y2024/V21/I3/349

参考文献

[1] MARTINI A, LOVELL DJ, ALBANI S, et al.Juvenile idiopathic arthritis[J]. Nat Rev Dis Primers, 2022, 8(1): 5.
[2] LI CF, SHI XW.Treatment strategies of juvenile idiopathic arthritis in biologics era[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(23): 2318-2322.
[3] CHOY EH, DE BF, TAKEUCHI T, et al.Translating IL-6 biology into effective treatments[J]. Nat Rev Rheumatol, 2020, 16(6): 335-345.
[4] LIU YT, ZENG LW, WANG NN.Study on the effect of tocilizumab combined with celecoxib on inflammatory response in patients with moderate to severe rheumatoid arthritis[J]. Journal of China Prescription Drug(中国处方药), 2023, 21(7): 103-106.
[5] LI YB, LIU J, HU J, et al.Application of biological agents in the treatment of systemic juvenile idiopathic arthritis[J]. Chinese Journal of Practical Pediatrics(中国实用儿科杂志), 2017, 32(4): 308-313.
[6] BONNY M, BUYSE V, SUYS E.Rapidly progressive malignant melanoma in a patient treated with tocilizumab[J]. J Am Acad Dermatol, 2012, 67(2): e78-e79.
[7] Roche Pharma (Schweiz) Ltd. Tocilizumab Injection Package Insert, JS20170010[EB/OL]. (2017-09-25)[2023-03-15]. https://db.yaozh.com/instruct/65541956.html.
[8] SHU B, JIANG W, SHEN AZ.Literature analysis of adverse drug reactions induced by tocilizumab[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(4): 369-376.
[9] CANSEVER M, ŞAHIN N, DURSUN I, et al.Successful slow desensitization to tocilizumab in a 15-year-old patient[J]. J Investig Allergol Clin Immunol, 2018, 28(6): 436-438.
[10] SOYER O, DEMIR S, BILGINER Y, et al.Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases[J]. Pediatr Allergy Immunol, 2019, 30(8): 833-840.
[11] PARK EH, LEE EY, SHIN K, et al.Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review[J]. Rheumatol Int, 2020, 40(5): 791-798.
[12] Genentech. ACTEMRA^®(TOCILIZUMAB)[EB/OL].(2019-06-01)[2020-03-08]. https://www.gene.com/download/pdf/actemra_prescribing.pdf.
[13] MoH, NMPA. Adverse Drug Reaction Reporting and Monitoring Management Measures[EB/OL]. (2004-03-04)[2020-03-01]. http://www.nhc.gov.cn/wjw/bmgz/200804/8fd34a2690c04eeeb266856bf364931e.shtml.
[14] LI W, YANG T, WANG C.Current status and progress of prevention and treatment of chronic obstructive pulmonary disease in China[J]. Journal of Chinese Research Hospitals(中国研究型医院), 2020, 7(5): 78-84.
[15] LI M, SUN H, ZHANG JS.Update in the clinical research of drug-induced anaphylactic shock[J]. Journal of Practical Shock(实用休克杂志), 2021, 5(1): 1-5.
[16] XIANG L, WAN WL, QU ZH, et al.Recommedations for the diagnosis and treatment of anaphylaxis in Chinese children[J]. Chinese Journal of Applied Clinical Pediatrics(中华实用儿科临床杂志), 2021, 36(6): 410-416.
[17] Information Product. Tocilizumab[EB/OL].(2019-09-19)[2023-03-08]. https://www.drugs.com/cdi/tocilizumab-intravenous.html.
[18] JUSTET A, NEUKIRCH C, POUBEAU P, et al.Successful rapid tocilizumab desensitization in a patient with still disease[J]. J Allergy Clin Immunol Pract, 2014, 2(5): 631-632.

托珠单抗注射液致过敏性休克1例分析

One case of allergic shock caused by tocilizumab injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘洁, 张建民, 张晓朦, 刘芳, 宋远, 钟旭丽. 某院中成药说明书的儿科用药风险分析与管理思考[J]. 中国药物警戒, 2024, 21(4): 422-427.
[2]	杨波, 王梦娇, 胡丽丽, 王来成, 李倩, 孔飞飞, 吕冬梅, 沈佳妮. 385例PD-1抗肿瘤治疗的安全性研究及风险因素分析[J]. 中国药物警戒, 2024, 21(4): 447-450.
[3]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[4]	李少强, 孔旭东, 李朋梅. 注射用奥美拉唑钠致低钠血症1例分析[J]. 中国药物警戒, 2024, 21(4): 461-463.
[5]	伍诗琪, 闫素英, 张青霞. 艾多沙班药代动力学相互作用研究进展[J]. 中国药物警戒, 2024, 21(4): 473-480.
[6]	黄焕均, 麦嘉恒, 张云惠, 郭晨晨, 梁蔚婷. 613例抗肿瘤药物的不良反应分析[J]. 中国药物警戒, 2024, 21(3): 324-328.
[7]	吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.
[8]	杨雪婷, 何波, 闫鸿丽, 李冬梅. 克拉霉素致急性短暂性抑郁症不良反应1例分析[J]. 中国药物警戒, 2024, 21(3): 352-354.
[9]	孙绮悦, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 基于多动物模型药效评价体系研究羚羊感冒口服液儿童用药剂量[J]. 中国药物警戒, 2024, 21(2): 121-126.
[10]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[11]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[12]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[13]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[14]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[15]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.